NCT07521852 2026-04-22
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
TaiRx, Inc.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Suzhou Abogen Biosciences Co., Ltd.
ImmVirx Pty Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Chipscreen Biosciences, Ltd.
Akeso
TJ Biopharma Co., Ltd.